| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update JS Smolen, R Landewé, J Bijlsma, G Burmester, K Chatzidionysiou, ... Annals of the rheumatic diseases 76 (6), 960-977, 2017 | 5903 | 2017 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update JS Smolen, RBM Landewé, JWJ Bijlsma, GR Burmester, M Dougados, ... Annals of the rheumatic diseases 79 (6), 685-699, 2020 | 2908 | 2020 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update JS Smolen, RBM Landewé, SA Bergstra, A Kerschbaumer, A Sepriano, ... Annals of the rheumatic diseases 82 (1), 3-18, 2023 | 1122* | 2023 |
| Neurophysiologic evidence for a central sensitization in patients with fibromyalgia JA Desmeules, C Cedraschi, E Rapiti, E Baumgartner, A Finckh, P Cohen, ... Arthritis & Rheumatism 48 (5), 1420-1429, 2003 | 762 | 2003 |
| Long‐term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta‐analysis A Finckh, MH Liang, CM van Herckenrode, P De Pablo Arthritis Care & Research: Official Journal of the American College of …, 2006 | 659 | 2006 |
| Global epidemiology of rheumatoid arthritis A Finckh, B Gilbert, B Hodkinson, SC Bae, R Thomas, KD Deane, ... Nature Reviews Rheumatology 18 (10), 591-602, 2022 | 550 | 2022 |
| EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis DM Gerlag, K Raza, LGM Van Baarsen, E Brouwer, CD Buckley, ... Annals of the rheumatic diseases 71 (5), 638-641, 2012 | 550 | 2012 |
| Phase 1 trials of rVSV Ebola vaccine in Africa and Europe ST Agnandji, A Huttner, ME Zinser, P Njuguna, C Dahlke, JF Fernandes, ... New England Journal of Medicine 374 (17), 1647-1660, 2016 | 521 | 2016 |
| Prevotella copri in individuals at risk for rheumatoid arthritis D Alpizar-Rodriguez, TR Lesker, A Gronow, B Gilbert, E Raemy, ... Annals of the rheumatic diseases 78 (5), 590-593, 2019 | 420 | 2019 |
| Inhibition of interleukin‐33 signaling attenuates the severity of experimental arthritis G Palmer, D Talabot‐Ayer, C Lamacchia, D Toy, CA Seemayer, S Viatte, ... Arthritis & rheumatism: official journal of the American College of …, 2009 | 408 | 2009 |
| Inequities in access to biologic and synthetic DMARDs across 46 European countries P Putrik, S Ramiro, TK Kvien, T Sokka, M Pavlova, T Uhlig, A Boonen, ... Annals of the rheumatic diseases 73 (1), 198-206, 2014 | 398 | 2014 |
| Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review A Rubbert-Roth, A Finckh Arthritis research & therapy 11, 1-12, 2009 | 380 | 2009 |
| The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial A Huttner, JA Dayer, S Yerly, C Combescure, F Auderset, J Desmeules, ... The Lancet Infectious Diseases 15 (10), 1156-1166, 2015 | 331 | 2015 |
| Fibromyalgia: a randomised, controlled trial of a treatment programme based on self management C Cedraschi, J Desmeules, E Rapiti, E Baumgartner, P Cohen, A Finckh, ... Annals of the rheumatic diseases 63 (3), 290-296, 2004 | 324 | 2004 |
| B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor … A Finckh, A Ciurea, L Brulhart, D Kyburz, B Möller, S Dehler, S Revaz, ... Arthritis & Rheumatism 56 (5), 1417-1423, 2007 | 319 | 2007 |
| Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative A Baillet, L Gossec, L Carmona, M de Wit, Y van Eijk-Hustings, ... Annals of the rheumatic diseases 75 (6), 965-973, 2016 | 309 | 2016 |
| The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials MD Balow, K Costenbader, L Crofford, MD Finckh, CP Gordon, ... Arthritis & Rheumatism 54 (2), 421-432, 2006 | 245 | 2006 |
| Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis A Finckh, JF Simard, C Gabay, PA Guerne Annals of the rheumatic diseases 65 (6), 746-752, 2006 | 244 | 2006 |
| EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors M Kostine, A Finckh, CO Bingham, K Visser, J Leipe, H Schulze-Koops, ... Annals of the rheumatic diseases 80 (1), 36-48, 2021 | 242 | 2021 |
| Comparison of drug retention rates and causes of drug discontinuation between anti–tumor necrosis factor agents in rheumatoid arthritis SMD Pan, S Dehler, A Ciurea, HR Ziswiler, C Gabay, A Finckh Arthritis Care & Research: Official Journal of the American College of …, 2009 | 238 | 2009 |
